TEQUILA DON JULIO PARTNERS WITH MEXICO’S ACCLAIMED PANADERÍA ROSETTA TO BRING THE SPIRIT OF DÍA DE MUERTOS TO THE WORLD
Tequila Don Julio continues to celebrate and share Mexican culture globally with Panadería Don Julio pop-ups for Día de Muertos, offering guests the chance to experience pan de muerto, one of the holiday’s most cherished traditions ATOTONILCO EL ALTO, JALISCO, Mexico, Oct. 13, 2025 /PRNewswire/ — Tequila Don Julio continues its commitment to sharing Mexican culture […]
World’s Largest AI-in-Projects Study Reveals: Artificial Intelligence Is Revolutionizing How $48 Trillion in Projects Are Delivered
The 2025 Global AIPM Survey, the most comprehensive study of its kind, shows that organizations using AI are executing projects up to 25% faster and achieving measurable savings, marking a turning point in how transformation is led worldwide. LONDON, Oct. 13, 2025 /PRNewswire/ — AI and the Transformation Age: How Projects Are Powering the Future of […]
Nanoscope Therapeutics Announces Multiple Presentations at the American Academy of Ophthalmology 2025 Annual Meeting
DALLAS, Oct. 13, 2025 /PRNewswire/ — Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to retinal degeneration, today announced multiple presentations at the American Academy of Ophthalmology (AAO) 2025 Annual Meeting, to be held October 18-20, 2025 in Orlando, FL, […]
Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis
15 out of 18 complete responders (83%) demonstrate continued complete response with median follow-up of 36 months Reduction in surgeries compared to year prior to treatment with PAPZIMEOS was observed in 86% of patients in Year 1, 91% in Year 2, and 95% in Year 3 No new safety events observed during long-term follow-up GERMANTOWN, […]
NetActuate Supports Raleigh-Durham-Chapel Hill Triangle with Investments in Technology Access and Education
RALEIGH, N.C., Oct. 13, 2025 /PRNewswire/ — NetActuate, a global provider of network and infrastructure services, is proud to reaffirm its commitment to the Raleigh-Durham-Chapel Hill Triangle by investing in local technology access and education. With staff headquarters, a 24/7 Network Operations Center (NOC), and a major data center based in Raleigh, NetActuate is deeply embedded […]
Pest Control Market Size & Share to Surpass USD 44.3 Billion by 2035, Growing at a CAGR 6.4% | Vantage Market Research
NEW YORK, Oct. 13, 2025 /PRNewswire/ — The Global Pest Control Market is poised for steady expansion, projected to rise from USD 26.9 billion in 2024 to USD 44.3 billion by 2035, growing at a CAGR of 6.4% during 2025–2035. The market’s momentum reflects escalating pressures from climate-driven infestations, rapid urbanization, stricter hygiene mandates, and a […]
Reins CEO Chris Buttenham to speak at Service World Expo 2025
The leading expert in alternative equity solutions for the skilled trades will share insights and best practices to support employee retention LAS VEGAS, Oct. 13, 2025 /PRNewswire/ — Reins, a pioneering technology firm dedicated to empowering privately owned businesses through alternative equity solutions, announces that its CEO and co-founder, Chris Buttenham, will be a featured speaker […]
Lupin annonce la présentation de données de phase I sur le LNP3693 (agoniste de STING) au congrès ESMO 2025
MUMBAI, Inde, NAPLES, Floride, États-Unis et BERLIN, Allemagne, 13 octobre 2025 /PRNewswire/ — Lupin Limited (Lupin) (BSE : 500257) (NSE : LUPIN) (REUTERS : LUPIN.BO) (BLOOMBERG : LPCIN) présentera les données de son essai clinique de phase Ia évaluant le LNP3693, un agoniste de STING, lors du congrès ESMO à Berlin, en Allemagne, du 17 au 21 octobre 2025. La présentation, […]
Lupin kündigt Präsentation von Phase-1-Daten zu LNP3693 (STING-Agonist) auf dem ESMO-Kongress 2025 an
MUMBAI, Indien, und NAPLES, Florida, und BERLIN, 13. Oktober 2025 /PRNewswire/ — Der globale Pharmakonzern Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) wird vom 17. bis 21. Oktober 2025 auf dem ESMO-Kongress in Berlin Daten aus der klinischen Phase-1a-Studie mit dem STING-Agonisten LNP3693 vorstellen. Die Präsentation mit dem Titel „A phase […]
Lupin Announces Presentation of Phase 1 Data on LNP3693 (STING agonist) at the ESMO Congress 2025
MUMBAI, India and NAPLES, Fla. and BERLIN, Oct. 13, 2025 /PRNewswire/ — Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) will present data from its Phase 1a clinical trial evaluating LNP3693, a STING agonist, at the ESMO Congress in Berlin, Germany, from October 17 to October 21, 2025. The […]